Adverse Effects of RBC Transfusions: A Unifying Hypothesis

Phase 2

Completed

• Conditions: Healthy Volunteers
• Interventions: Biological: Fresh blood; Biological: Aged blood

• Registration Number: NCT00838331
• Lead Sponsor: Emory University

Brief Summary

Transfusion of red blood cells is often used in critically ill patients with low red blood cell counts to prevent disease progression and death. Recent studies suggest that the use of "aged" versus "fresh" red blood cells are associated with worse clinical outcomes. There is evidence that red blood cells work with the cells lining our blood vessels to produce a variety of substances that normally cause arteries to relax and increase blood supply. Two of these substances are called nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF). The investigators are trying to determine the nature of these substances in human beings when they are transfused "aged" versus "fresh" red blood cells. It is their thought that "aged" red blood cells have less of the substances (NO and EDHF) that naturally relax our arteries and further changes the blood supply. One way to determine this is to transfuse a subject's own "aged" and "fresh" red blood cells and inject substances such as L-NMMA (L-NG monomethyl arginine) and TEA (tetraethylammonium chloride), which block the production of NO and EDHF respectively, and then, study what happens to the blood flow.

There is evidence that red blood cells produce NO, which normally causes arteries to relax and increase blood supply. The investigators will try to determine the nature of NO in red blood cells and whether the amount of this substance is altered because of different blood processing and storage techniques. It is their thought that "aged" red blood cells have less NO that naturally relaxes our arteries and further changes the blood supply. This study is designed to determine the most ideal way of storing and processing blood.

Detailed Description

Transfusion of red blood cells (RBCs) is often effective at preventing morbidity and mortality in anemic patients. In contrast, recent studies indicate that some RBC components may have functional defects ("RBC storage lesions") that actually cause morbidity and mortality when transfused. For example, patients transfused with RBCs stored \>14 days have statistically worse outcomes than those receiving "fresher" RBC units. In addition to the age of stored RBCs, the volume transfused may be important. The TRICC study showed that specific patients whose transfusions were limited by a restrictive trigger (RBCs transfusions only when hemoglobin \[Hb\] \< 7 g/dL) had significantly better outcomes than those transfused with a more liberal trigger (\[Hb\] \< 10 g/dL Hb). This finding has been particularly difficult to understand since conventional wisdom suggests that an elevated \[Hb\] should be beneficial because it supports increased O2 delivery. Recipient-specific factors may also contribute to the occurrence of these adverse events. Unfortunately, these events have been difficult to investigate because up to now they have existed only as "statistical occurrences" of increased morbidity and mortality in large data sets. There are currently no clinical or laboratory methods to detect or study them in individual patients.

The microcirculation is composed of a continuum of small vessels including small arterioles, capillaries, and post-capillary venules. The microcirculation represents an actively-adjusting vascular circuit that matches blood flow (and O2 delivery) to local tissue oxygen demands. While the physiologic mechanisms that match O2 delivery to local requirements are incompletely understood, endothelium-derived nitric oxide (NO) clearly plays an important role. Interestingly, recent work has revealed that in addition to transporting O2 and CO2, the RBC also controls local NO concentrations and thus may also play a surprisingly important role in regulating blood flow in the microcirculation.

Herein, the investigators bring together previously unconnected data to propose a unifying hypothesis, centered on insufficient NO bioavailability (INOBA), to explain the increased morbidity and mortality observed in some patients following RBC transfusion. In this model, variables associated with RBC units (storage time; 2,3-DPG concentration) and transfusion recipients (endothelial dysfunction; hematocrit \[Hct\]) collectively lead to changes in NO levels in vascular beds. Under certain circumstances, these variables are "aligned" such that NO concentrations are markedly reduced, leading to vasoconstriction, decreased local blood flow and insufficient O2 delivery to end organs. Under these circumstances, the likelihood of morbidity and mortality escalates. The INOBA hypothesis is attractive because of its explanatory power and because it leads to a number of readily testable predictions, which will be investigated in the following aims:

Aim 1: To investigate the effects of blood processing and storage (using standard FDA-approved conditions) on NO production and scavenging by human RBCs/Hb in vitro. Using sensitive biochemical assays (electron spin resonance \[ESR\]) and a rat aortic ring in vitro bioassay, the investigators will test the effects of RBC storage time, leukoreduction, and irradiation on NO synthesis and/or scavenging by intact RBCs and free Hb. Modifications such as washing and rejuvenation will be investigated as possible approaches to correct abnormalities in NO bioavailability.

Aim 2: To transfuse healthy volunteers and investigate the effects of storage-related RBC changes on blood flow, tissue oxygenation, and biomarkers of cardiovascular function. The investigators will determine whether RBCs prepared and stored under conditions that alter NO bioavailability in vitro (Aim 1) inhibit NO-mediated vasodilation, reduce tissue perfusion, and decrease tissue O2 delivery in healthy transfusion recipients in vivo. The role of 2,3-DPG depletion as well as exercise-induced O2 demand will also be investigated with these specialized experimental systems.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2009-02-05
• Study First Submitted QC: 2009-02-05
• Study First Posted: 2009-02-06
• Study Start: 2009-04
• Primary Completion: 2013-05
• Study Completion: 2013-10
• Results First Submitted: 2015-02-13
• Status Verified: 2015-03
• Results First Submitted QC: 2015-03-04
• Last Update Submitted: 2015-03-04
• Results First Posted: 2015-03-06
• Last Update Posted: 2015-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Healthy male or female volunteers (age 21-60 years)

Must meet guidelines for blood donors including:

• standard blood donor history questionnaire
• body weight of at least 110 lbs
• hemoglobin concentration of at least 12.5 gm/dL
• body temperature of no more than 99.5 oF
• pulse of 50-100 bpm
• blood pressure < 180/100
• test negative for the standard battery of blood donor screening tests (anti-HIV, HIV RNA, anti-HCV, HCV RNA, HBsAg, anti-HBc, anti-HTLV-I/II, and WNV RNA)

Aim 1:

Read More

Exclusion Criteria

• Failure to pass the blood donor history questionnaire
• Positive results on the standard battery of blood donor screening tests
• Failure to meet criteria for donation

Aim 2:

Inclusion Criteria:

• Healthy male or female volunteers (age 21-80 years)

Exclusion Criteria:

• Presence of intercurrent illness or other chronic diseases
• Renal failure (creatinine>1.4 mg/dl)
• Pregnancy
• Allergies to aspirin
• Bleeding disorders
• Uncontrolled hypertension with BP > 180 mmHg systolic and > 120 mmHg diastolic
• Acute infection in previous 4 weeks
• History of substance abuse
• Liver failure (Liver enzymes >2x normal)
• Inability to give informed consent
• Inability to return to Emory for follow-up

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Fresh blood, then aged blood	Fresh blood	-
Fresh blood, then aged blood	Aged blood	-

Primary Outcome Measures

Name	Time	Method
The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow.	5 years	The primary outcome measures are changes in forearm blood flow (FBF) in recipients of fresh or stored RBC transfusions in response to acetylcholine. Secondary measures include changes in FBF with acetylcholine with or without L-NMMA, and changes in FBF with forearm exercise. In addition, flow mediated dilation (FMD) measurements will also be used to assess changes in brachial artery diameter before and after fresh vs aged RBC transfusions.

Trial Locations

Locations (1)

Emory University; 🇺🇸 Atlanta, Georgia, United States